文献速递甲状腺疾病

Graves病自身抗体在甲状腺细胞与眼眶成纤维细胞中刺激活性不同,临床检测未能反映

Graves' Autoantibodies Exhibit Different Stimulating Activities in Cultures of Thyrocytes and Orbital Fibroblasts Not Reflected by Clinical Assays.
PubMed 文献 · Thyroid · 2021-11-29

研究比较了Graves甲亢(GH)与Graves眼病(GO)患者促甲状腺激素受体刺激抗体(TSAb)在体外对正常甲状腺细胞和GO患者眼眶成纤维细胞的刺激活性,并与工程细胞cAMP-PKA报告基因检测对比。发现TSAb在工程细胞的cAMP刺激与甲状腺细胞TG分泌及眼眶成纤维细胞HA分泌正相关,但GH来源TSAb更有效刺激甲状腺细胞,GO来源TSAb更有效刺激眼眶成纤维细胞,临床检测无法区分二者。

要点

  • 临床TSAb检测与甲状腺细胞和眼眶成纤维细胞刺激正相关,但不能区分GH与GO来源抗体。
  • GH来源TSAb对甲状腺细胞刺激更强,GO来源TSAb对眼眶成纤维细胞刺激更强。
  • TSAb在体外对TSHR激活具有细胞选择性,提示临床检测需改进。

核心结论

  • 临床TSAb检测(cAMP-PKA通路)与甲状腺细胞和眼眶成纤维细胞刺激相关,但不能区分GH与GO来源TSAb。
  • 体外TSAb对TSHR激活具有选择性:GO来源TSAb更有效刺激眼眶成纤维细胞,GH来源TSAb更有效刺激甲状腺细胞。

研究设计与样本

  • 体外原代培养正常人类甲状腺细胞和GO患者眼眶成纤维细胞,检测TSAb刺激后甲状腺细胞TG分泌和眼眶成纤维细胞HA分泌。
  • 同时用工程化表达TSHR的细胞检测cAMP产生,模拟临床TSAb检测。
  • 比较GH单独患者与GO患者(伴GH)来源TSAb的刺激差异。

主要发现

  • 工程细胞cAMP产生与甲状腺细胞TG分泌及眼眶成纤维细胞HA分泌均呈正相关。
  • GH患者来源TSAb刺激甲状腺细胞比GO患者来源TSAb更有效。
  • GO患者来源TSAb激活眼眶成纤维细胞比GH患者来源TSAb更有效。

临床怎么用

  • 临床TSAb检测结果需结合临床表现解读,不能仅凭检测区分GH与GO。
  • 未来可探索针对不同细胞类型或信号通路的检测以更好反映TSAb致病选择性。

局限性

  • 研究为体外原代培养实验,不能完全代表体内复杂环境。
  • 未报告具体样本量、P值等统计细节。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Background: The pathogenesis of Graves' hyperthyroidism (GH) and associated Graves' orbitopathy (GO) appears to involve stimulatory autoantibodies (thyrotropin receptor [TSHR]-stimulating antibodies [TSAbs]) that bind to and activate TSHRs on thyrocytes and orbital fibroblasts. In general, measurement of circulating TSHR antibodies by clinical assays correlates with the status of GH and GO. However, most clinical measurements of TSHR antibodies use competitive binding assays that do not distinguish between TSAbs and antibodies that bind to but do not activate TSHRs. Moreover, clinical assays for TSAbs measure stimulation of only one signaling pathway, the cyclic adenosine monophosphate (cAMP)-protein kinase A (PKA) pathway, in engineered cells that are not thyrocytes or orbital fibroblasts. We determined whether measuring TSAbs by a cAMP-PKA readout in engineered cells accurately reveals the efficacies of stimulation by these antibodies on thyrocytes and orbital fibroblasts. Methods: We measured TSAb stimulation of normal human thyrocytes and orbital fibroblasts from patients with GO in primary cultures in vitro. In thyrocytes, we measured secretion of thyroglobulin (TG) and in orbital fibroblasts secretion of hyaluronan (hyaluronic acid [HA]). We also measured stimulation of cAMP production in engineered TSHR-expressing cells in an assay similar to clinical assays. Furthermore, we determined whether there were differences in stimulation of thyrocytes and orbital fibroblasts by TSAbs from patients with GH alone versus from patients with GO understanding that patients with GO have accompanying GH. Results: We found a positive correlation between TSAb stimulation of cAMP production in engineered cells and TG secretion by thyrocytes as well as HA secretion by orbital fibroblasts. However, TSAbs from GH patients stimulated thyrocytes more effectively than TSAbs from GO patients, whereas TSAbs from GO patients were more effective in activating orbital fibroblasts than TSAbs from GH patients. Conclusions: Clinical assays of stimulation by TSAbs measuring activation of the cAMP-PKA pathway do correlate with stimulation of thyrocytes and orbital fibroblasts; however, they do not distinguish between TSAbs from GH and GO patients. In vitro, TSAbs exhibit selectivity in activating TSHRs since TSAbs from GO patients were more effective in stimulating orbital fibroblasts and TSAbs from GH patients were more effective in stimulating thyrocytes.

来源:Thyroid,查看原文。版权归原作者所有。

引用

  1. Krieger CC, Kahaly GJ, Azam A, et al. Graves' Autoantibodies Exhibit Different Stimulating Activities in Cultures of Thyrocytes and Orbital Fibroblasts Not Reflected by Clinical Assays. Thyroid. 2021. PMID: 34714162. doi:10.1089/thy.2021.0326

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。